| 2019/24/10 - 18:00 |
|
Cash position and activity update for Q3 2019
|
pdf
|
| 2019/13/09 - 08:00 |
|
Message from the Board of Directors
|
pdf
|
| 2019/09/09 - 08:00 |
|
Cyrille Tupin appointed CEO
|
pdf
|
| 2019/06/09 - 07:00 |
|
2019 Half-year results
|
pdf
|
| 2019/27/08 - 18:30 |
|
Change of name and stock symbol/mnemonic of ABIONYX Pharma shares (formerly CERENIS Therapeutics) as of August 29, 2019
|
pdf
|
| 2019/26/08 - 20:20 |
|
ABIONYX Pharma announces appointment of a new member to the Board
|
pdf
|
| 2019/18/07 - 19:29 |
|
CERENIS Therapeutics announces cash position and activity update for Q2 2019
|
pdf
|
| 2019/24/06 - 22:25 |
|
Cerenis Therapeutics announces the results of the Annual Combined General Meeting of Shareholders
|
pdf
|
| 2019/14/06 - 19:59 |
|
Cerenis announces the success of a capital increase for the benefit of persons belonging to specific categories
|
pdf
|
| 2019/13/06 - 21:00 |
|
Cerenis announces the launch of a capital increase for the benefit of persons belonging to specific categories
|
pdf
|
| 2019/18/04 - 18:02 |
|
Cash position and activity update for Q1 2019
|
pdf
|
| 2019/27/03 - 18:21 |
|
Cerenis Therapeutics and H4Orphan Pharma enter into exclusive negotiations to consider a strategic merger
|
pdf
|
| 2019/24/01 - 19:12 |
|
2018 Annual Results and clinical update
|
pdf
|
| 2019/23/01 - 18:15 |
|
2019 Financial agenda
|
pdf
|
